Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease

Abstract Background and aims When patients with sickle cell disease have appropriate indications, they can be prescribed hydroxyurea (HU) and deferasirox (DFX) concurrently despite little knowledge about how the two medications interact. We wished to analyze whether there was evidence of adverse int...

Full description

Bibliographic Details
Main Authors: Trisha E. Wong, Jhaqueline Valle, Susan Paulukonis
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Health Science Reports
Subjects:
Online Access:https://doi.org/10.1002/hsr2.323